Akademik Veri Yönetim Sistemi
CHEMISTRYSELECT, cilt.9, sa.7, 2024 (SCI-Expanded)
This study introduces an innovative approach to enhance breast cancer treatment by combining Boric Acid (BA) and Tannic Acid (TA) with Paclitaxel (PTX) within gelatin/sodium alginate (Gel/NaAlg) nanoparticles, resulting in a synergistic combination therapy. The methodology involved integrating PTX, TA, and BA into the polymeric framework using an emulsion cross-linking method. The resulting nanoparticles underwent rigorous characterization, confirming their suitability as a controlled release platform. Techniques such as Scanning Electron Microscope (SEM), Differential Scanning Calorimetry (DSC), X-ray Diffractometry (XRD), and Fourier Transform Infrared Spectroscopy (FTIR) were employed for thorough analysis. The synthesized nanoparticles demonstrated a size below 204 nm, and extensive analyses confirmed their structural integrity and composition. Notably, Gel/NaAlg/PTX/BA/TA nanoparticles exhibited superior drug release kinetics compared to other formulations, offering a promising strategy for controlled release of hydrophobic drugs like PTX. Entrapment efficiency ranged from 49.84 % to 63.38 %, and drug loading capacities spanned from 49.81 to 61.42 mu g/mg. This study pioneers a novel approach in breast cancer therapy by incorporating BA and TA into PTX-loaded Gel/NaAlg nanoparticlesThese findings emphasize the importance of continued exploration in innovative drug delivery systems for more effective cancer interventions. This study introduces an innovative breast cancer treatment, utilizing Gel/NaAlg nanoparticles to combine Boric Acid (BA), Tannic Acid (TA), and Paclitaxel (PTX). The developed system demonstrates notable efficacy against MCF-7 cells, underscoring its transformative potential in breast cancer therapy. Enhanced aqueous solubility and improved targeting underscore the innovation, emphasizing the ongoing importance of exploring innovative drug delivery for more effective cancer interventions. image